Phase 1 Start

INSM: Phase1_Start: A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants

Name: Phase1_Start: A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants
Start: 2026-10-29
End: 2026-10-29

October 29, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 29, 2026
Company: INSMED Inc (INSM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 1 Start

Phase1_Start: A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants

October 29, 2026

INSM overview →

Company: INSMED Inc (INSM)

Other upcoming events for INSM

Phase 3 StartPhase3_Start: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel Group Study of Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Progressive Pulmonary Fibrosis (PPF)-PALM-PPF

Dec 1, 2026